"It only means fast tracking (again!) for reimbursement (which means money! no point having products that are not reimbursed by government programs or insurers)."
No it doesn't. Unless by "fast-tracking", you mean "not making avoidable mistakes". The purpose of the programme is to reduce the risk that companies will conduct clinical studies which do not allow for appropriate health economic outcomes to be assessed. As indeed, it says in the announcement.
So, not fast tracked. Same old reimbursement process, but hopefully with data which the reimbursement authorities consider meaningful.
Ann: Positive EMA Meeting For Phase 3 Disc Repair Program, page-7
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
-0.030(2.08%) |
Mkt cap ! $1.627B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $1.409M | 990.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 15988 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.42 | 12068 | 8 |
View Market Depth
| Last trade - 12.32pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |